Abstract
Bacteriophage (phage) evolved as bacterial viruses, but can be adapted to transduce mammalian cells through ligand-directed targeting to a specific receptor. We have recently reported a new generation of hybrid prokaryotic–eukaryotic vectors, which are chimeras of genetic cis-elements of recombinant adeno-associated virus and phage (termed AAVP). This protocol describes the design and construction of ligand-directed AAVP vectors, production of AAVP particles and the methodology to transduce mammalian cells in vitro and to target tissues in vivo after systemic administration. Targeted AAVP particles are made in a two-step process. First, a ligand peptide of choice is displayed on the coat protein to generate a targeted backbone phage vector. Then, a recombinant AAV carrying a mammalian transgene cassette is inserted into an intergenomic region. High-titer suspensions (∼1010–1011 transducing units per μl) can be produced within 3 days after vector construction. Transgene expression by targeted AAVP usually reaches maximum levels within 1 week.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hajitou, A. et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125, 385–398 (2006).
Watkins, S.J., Mesyanzhinov, V.V., Kurochkina, L.P. & Hawkins, R.E. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4, 1004–1012 (1997).
Wickham, T.J. et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J. Virol. 71, 7663–7669 (1997).
Miller, C.R. et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58, 5738–5748 (1998).
Martin, F. et al. Retrovirus targeting by tropism restriction to melanoma cells. J. Virol. 73, 6923–6929 (1999).
Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052–1056 (1999).
Vigne, E. et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 73, 5156–5161 (1999).
Reynolds, P.N. et al. A targetable injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo . Mol. Ther. 2, 562–578 (2000).
Wickham, T.J. Targeting adenovirus. Gene Ther. 7, 110–114 (2000).
Trepel, M., Grifman, M., Weitzman, M.D. & Pasqualini, R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum. Gene Ther. 11, 1971–1981 (2000).
Trepel, M., Arap, W. & Pasqualini, R. Exploring vascular heterogeneity for gene therapy targeting. Gene Ther. 7, 2059–2060 (2000).
Müller, O.J. et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040–1046 (2003).
Lieber, A. AAV display-homing in on the target. Nat. Biotechnol. 21, 1011–1013 (2003).
Barrow, P.A. & Soothill, J.S. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5, 268–271 (1997).
Barbas III, C.F., Burton, D.R., Scott, J.K. & Silverman, G.J. Phage Display: A Laboratory Manual (Cold Spring Harbor Press, Cold Spring Harbor, NY, 2001).
Ivanenkov, V.V., Felici, F. & Menon, A.G. Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim. Biophys. Acta 1448, 463–472 (1999).
Larocca, D. et al. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J. 13, 727–734 (1999).
Poul, M.A. & Marks, J.D. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J. Mol. Biol. 288, 203–211 (1999).
Sergeeva, A., Kolonin, M.G., Molldrem, J.J., Pasqualini, R. & Arap, W. Display technologies: application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev. 58, 1622–1654 (2006).
Monaci, P., Urbanelli, L. & Fontana, L. Phage as gene delivery vectors. Curr. Opin. Mol. Ther. 3, 159–169 (2001).
Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121–127 (2002).
Pentz, R.D. et al. Ethics guidelines for research with the recently dead. Nat. Med. 11, 1145–1149 (2005).
Krag, D.N. et al. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 66, 7724–7733 (2006).
Koivunen, E. et al. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768–774 (1999).
Pasqualini, R., Koivunen, E. & Ruoslahti, E. αv integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542–546 (1997).
Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380 (1998).
Kolonin, MG, Saha, PK, Chan, L, Pasqualini, R & Arap, W. Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 10, 625–632 (2004).
Ellerby, H.M. et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5, 1032–1038 (1999).
Pasqualini, R., Arap, W., Rajotte, D. & Ruoslahti, E. In vivo phage display. in Phage Display: A Laboratory Manual (eds. Barbas III, C.F., Burton, D.R., Scott, J.K. & Silverman, G.J.) Ch. 22, 1–24 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2000).
Koivunen, E., Wang, B. & Ruoslahti, E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. BioTechnology 3, 265–270 (1995).
Smith, G.P. & Scott, J.K. Libraries of peptides and proteins displayed on filamentous phage. Meth. Enzymol. 217, 228–257 (1993).
Parmely, S.F. & Smith, G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73, 305–318 (1988).
Rajotte, D. et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102, 430–437 (1998).
Rajotte, D. & Ruoslahti, E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J. Biol. Chem. 274, 11593–11598 (1999).
http://www.biosci.missouri.edu/smithGP/PhageDisplayWebsite/PhageDisplayWebsiteIndex.html.
Tjuvajev, J.G. et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 58, 4333–4341 (1998).
Tjuvajev, J.G. et al. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo . Cancer Res. 59, 5186–5193 (1999).
Serikawa, T., Kikuchi, A., Sugaya, S., Suzuki, N., Kikuchi, H. & Tanaka, K. In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy. J. Control Rel. 113, 255–260 (2006).
Abe, A., Miyanohara, A. & Friedmann, T. Polybrene increases the efficiency of gene transfer by lipofection. Gene Ther. 5, 708–711 (1998).
Okada, Y., Okada, N., Mizuguchi, H., Hayakawa, T., Nakagawa, S. & Mayumi, T. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Ther. 12, 72–83 (2005).
Arap, M. et al. Model of unidirectional transluminal gene transfer. Mol. Ther. 9, 305–310 (2004).
Xiao, X., Li, J. & Samulski, R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224–2232 (1998).
Papaioannou, V.E. & Fox, J.G. Efficacy of tribromoethanol anesthesia in mice. Lab. Anim. Sci. 43, 189–192 (1993).
Soghomonyan, S. et al. Molecular PET imaging of HSV1-tk reporter gene expression by using 18F-FEAU. Nat. Protoc. doi: 10.1038/nprot.2007.49 (2007).
Acknowledgements
We thank Marco Arap, David Bier, Carlotta Cavazos, Carol M. Johnston, Erkki Koivunen, Darwin Lee, Frank C. Marini, Bradley H. Restel, Karen Schmidt, Yan Sun and Claudia Zompetta for advice and assistance. This work was funded by grants from the NIH (including the SPORE) and DOD (including the IMPACT) and by awards from the Gillson-Longenbaugh, the Keck Foundation and the Prostate Cancer Foundation (to R.P. and W.A.). A.H. received a Léon Fredericq award.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hajitou, A., Rangel, R., Trepel, M. et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc 2, 523–531 (2007). https://doi.org/10.1038/nprot.2007.51
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2007.51
This article is cited by
-
Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies
Cancer Gene Therapy (2020)
-
A Novel Molecular Design for a Hybrid Phage-DNA Construct Against DKK1
Molecular Biotechnology (2018)
-
An AAVP-based solid-phase transducing matrix for transgene delivery: potential for translational applications
Cancer Gene Therapy (2017)
-
Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors
Molecular Cancer (2015)
-
FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma
Scientific Reports (2015)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.